Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation

B. Poonkuzhali, A. Srivastava*, M. H. Quernin, D. Dennison, E. J. Aigrain, A. S. Kanagasabapathy, R. Krishnamoorthy, M. Chandy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


The pharmacokinetics of busulphan were studied in 23 thalassaemic children undergoing BMT. Patients received busulphan at a dose of either 16 mg/kg with cyclophosphamide and ATG (Group A) or 600 mg/m2 (with cyclophosphamide alone) (Group B) in 16 divided doses every 6 h over 4 days. Busulphan levels were analyzed by a modified GC-MS method. The dose of busulphan/kg for patients in group B was 64% (range 56-71%) higher than that for patients in group A. The mean AUC, Css, Cmax and MRV were significantly higher in group B as compared with group A for both doses 1 and 13. There was no significant difference in Vd/F, T1/2 and Kel between the two groups. A significant decrease in AUC and Css was found between 1st and 13th doses in group B, but not in group A. The Cl/F values in group A were significantly higher than those in group B after dose 1, but not after dose 13. No increase in toxicity due to the higher dose of busulphan was noted. We conclude that busulphan at 600 mg/m2 results in much higher systemic exposure to the drug as compared to 16 mg/kg, without increase in toxicity in children with beta thalassaemia major.

Original languageEnglish
Pages (from-to)5-11
Number of pages7
JournalBone Marrow Transplantation
Issue number1
Publication statusPublished - 1999
Externally publishedYes


  • Bone marrow transplantation
  • Busulphan
  • Pharmacokinetics
  • Thalassaemia

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

Cite this